AstraZeneca’s Full Takeover of SixPeaks Bio: Strategic Snapshot
Global biopharmaceutical company AstraZeneca’s option exercise to acquire the remaining equity of Swiss biotechnology startup SixPeaks Bio AG marks a calculated push into the fast-growing obesity and metabolic-health arena. The deal converts AstraZeneca’s 2024 minority stake into full ownership. After a US $15 million seed investment last year, AstraZeneca paid $170 million at closing, will remit $30 million in two years, and…
AstraZeneca announces $50bn pharma and R&D investment in US by 2030
Global biopharmaceutical company AstraZeneca has announced a $50 billion investment in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. The initiative, unveiled on July 22, 2025, includes a proposed multi-billion-dollar manufacturing facility in Virginia focused on chronic disease treatments such as oral GLP-1s, baxdrostat for hypertension, and PCSK9 inhibitors, which will be the company’s largest single-site investment globally. This expansion…